Compare Bank of Nova Scotia (BNS) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of Nova Scotia vs Citius Pharmaceuticals Inc — how do they compare? Bank of Nova Scotia trades at $89.03 (market cap $108.32B), while Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M). The key difference: Bank of Nova Scotia is far larger — about 5413.3× Citius Pharmaceuticals Inc's market cap, and Bank of Nova Scotia pays a 3.64% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| BNS | CTXR | |
|---|---|---|
Market Cap | $108.32B | $20.01M |
Sector | Financials | Health |
52-Week High | $90.29 | $1.82 |
52-Week Low | $56.41 | $0.48 |
Dividend Yield | 3.64% | — |
Enterprise Value | — | $16.23M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bank of Nova Scotia
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
